去勢抗性前列腺癌市場規模、佔有率和趨勢分析報告：按治療方法、地區和細分市場預測，2025-2030

去勢抗性前列腺癌市場成長與趨勢

預計到2030年，全球去勢抗性前列腺癌（CRPC）市場規模將達214.4億美元，預計2025年至2030年複合年成長率為8.7%。這一成長是由全球去勢抗性前列腺癌和不健康生活方式日益增加的負擔所推動的。

此外，預計新產品的推出和人們對前列腺癌的認知不斷提高，預計也將在預測期內提高市場成長率。此外，新藥採用的增加和強大的管道可能是預測期內加速市場成長的因素。

由於先進荷爾蒙療法在 CRPC 管理中的有效性，荷爾蒙療法細分市場在全球去勢抗性前列腺癌市場中佔據主導地位，到 2024 年，其銷售佔有率將達到 42.2%。此細分市場的推動因素是 Xtandi（Enzalutamide）市場滲透率的不斷提高以及 Erleada（阿帕魯胺）在美國、歐洲和日本的推出。此外，Xtandi 其他適應症的開發和核准正在推動該領域的成長。由於計劃在預測期內推出的強大管道藥物的存在，預計免疫療法也將成為成長最快的領域。

北美的壓倒性佔有率是由於高疾病負擔、技術進步、積極的政府政策、消費者對該疾病的認知提高以及醫療基礎設施的改善。該地區主要企業的存在也是推動該地區市場成長的重要因素。此外，印度和中國等新興國家的疾病盛行率很高，導致對改進治療的需求增加、醫療保健成本增加以及政府對腫瘤學和其他研究活動的資助增加。因此，這些因素預計將在預測期內推動亞太市場的發展。

該市場擁有賽諾菲、強生服務公司、輝瑞公司、安斯泰來製藥公司和拜耳公司等主要企業，因此難以滿足高資本要求，並為新進入者創造了機會。主要參與企業正在大力投資開發新藥，以維持其市場地位並獲得市場佔有率。

去勢抗性前列腺癌市場報告亮點

• 由於先進荷爾蒙療法在 CRPC 管理中的有效性，荷爾蒙療法細分市場在全球去勢抗性前列腺癌市場中佔據主導地位，到 2024 年，其銷售佔有率將達到 42.2%。
• 由於人們越來越認知到免疫療法在 CRPC 患者中提供持久反應和提高整體存活率的潛力，預計從 2025 年到 2030 年，免疫療法領域的複合年成長率將達到 11.9%。
• 2024年全球去勢抗性前列腺癌市場中，北美將佔最大的銷售佔有率，達到47.9%。
• 由於中國、日本和印度等人口稠密國家的前列腺癌盛行率不斷上升，預計亞太地區去勢抗性前列腺癌市場將在預測期內成長最快。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第 3 章去勢抗性前列腺癌市場變數、趨勢與範圍

• 市場體系展望
• 市場動態
  • 市場促進因素分析
  • 市場限制因素分析
• 營商環境分析
  • 產業分析-波特五力分析
  • PESTLE分析

第4章去勢抗性前列腺癌市場：治療方法業務分析

• 2024年及2030年治療市場佔有率
• 治療方法細分儀表板
• 2018-2030 年市場規模、預測與趨勢分析（按治療方法）
• 化療
• 荷爾蒙療法
• 免疫療法
• 放射治療

第5章去勢抗性前列腺癌市場：治療方法、地區、估計和趨勢分析

• 2024 年及 2030 年按地區分類的市場佔有率分析
• 區域市場儀表板
• 2018-2030年市場規模、預測趨勢分析
• 北美洲
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲
  • 英國
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 挪威
  • 瑞典
  • 丹麥
• 亞太地區
  • 日本
  • 中國
  • 印度
  • 泰國
  • 韓國
  • 澳洲
• 拉丁美洲
  • 巴西
  • 阿根廷
• 中東/非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 科威特

第6章 競爭狀況

• 參與者概覽
• 公司市場分析
• 公司分類
• 策略規劃
• 公司簡介/上市公司
  • Sanofi
  • Johnson & Johnson Services, Inc.
  • Pfizer, Inc.
  • Astellas Pharma, Inc.
  • Bayer AG

Castrate-resistant Prostate Cancer Market Growth & Trends:

The global castrate-resistant prostate cancer market size is expected to reach USD 21.44 billion in 2030 and is projected to grow at a CAGR of 8.7% from 2025 to 2030. This growth is driven by the rising global burden of castrate-resistant prostate cancer and unhealthy lifestyle.

In addition, the anticipated launch of new products and rising awareness of prostate cancer are likely to enhance the growth rate of the market over the forecast period. Moreover, the growing adoption of novel drugs and strong pipeline are factors likely to accelerate market growth during the forecast period.

The hormonal therapy segment dominated the global castrate-resistant prostate cancer market with a revenue share of 42.2% in 2024 due to the effectiveness of advanced hormonal therapies in managing CRPC. The segment is driven by increasing market penetration of Xtandi (enzalutamide) and the launch of Erleada (apalutamide) in the U.S., Europe, and Japan. Furthermore, the development and approval of an additional indication of Xtandi are driving the segment growth. In addition, immunotherapy is estimated to be the fastest-growing segment due to the presence of strong product pipeline drugs, which are projected to be launched during the forecast period.

North America's dominant share is attributable to high disease burden, technological advancements, proactive government measures, increased consumer awareness about the disease, and improvements in healthcare infrastructure. The presence of key players in this region is a key factor in boosting the growth of the market in the region. In addition, developing countries such as India and China are witnessing a high incidence of the disease that has resulted in an increase in the demand for improved therapeutics, an increase in healthcare expenditure, and a rise in government funding for oncology and other research activities. Thus, these factors are expected to drive the market in the Asia Pacific during the forecast period.

The presence of prominent players such as Sanofi; Johnson and Johnson Services, Inc.; Pfizer, Inc.; Astellas Pharma, Inc.; and Bayer AG in this market space significantly diminishes the opportunities of a new entry as it is difficult to match the high capital requirements. Key players are investing highly in the development of new molecules to maintain their presence in the market and acquire market share.

Castrate-resistant Prostate Cancer Market Report Highlights:

• The hormonal therapy segment dominated the global castrate-resistant prostate cancer market with a revenue share of 42.2% in 2024 due to the effectiveness of advanced hormonal therapies in managing CRPC.
• The immunotherapy segment is projected to grow at a CAGR of 11.9% from 2025 to 2030, driven by the increasing recognition of immunotherapy's potential to provide durable responses and improve overall survival in CRPC patients
• North America held the largest revenue share of 47.9% of the global castrate-resistant prostate cancer market in 2024
• Asia Pacific castrate-resistant prostate cancer market is anticipated to grow fastest throughout the forecast period, driven by the increasing prevalence of prostate cancer in densely populated countries such as China, Japan, and India

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Therapy
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Castrate-resistant Prostate Cancer Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTLE Analysis

Chapter 4. Castrate-resistant Prostate Cancer Market: Therapy Business Analysis

• 4.1. Therapy Market Share, 2024 & 2030
• 4.2. Therapy Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Therapy, 2018 to 2030 (USD Million)
• 4.4. Chemotherapy
  • 4.4.1. Chemotherapy market, 2018 - 2030 (USD Million)
• 4.5. Hormonal Therapy
  • 4.5.1. Hormonal Therapy market, 2018 - 2030 (USD Million)
• 4.6. Immunotherapy
  • 4.6.1. Immunotherapy market, 2018 - 2030 (USD Million)
• 4.7. Radiotherapy
  • 4.7.1. Radiotherapy market, 2018 - 2030 (USD Million)

Chapter 5. Castrate-resistant Prostate Cancer Market: Region Estimates & Trend Analysis by Therapy

• 5.1. Region Market Share Analysis, 2024 & 2030
• 5.2. Region Market Dashboard
• 5.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 5.4. North America
  • 5.4.1. North America castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.4.2. U.S.
    • 5.4.2.1. Key country dynamics
    • 5.4.2.2. Regulatory framework
    • 5.4.2.3. Competitive insights
    • 5.4.2.4. U.S. castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.4.3. Canada
    • 5.4.3.1. Key country dynamics
    • 5.4.3.2. Regulatory framework
    • 5.4.3.3. Competitive insights
    • 5.4.3.4. Canada castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.4.4. Mexico
    • 5.4.4.1. Key country dynamics
    • 5.4.4.2. Regulatory framework
    • 5.4.4.3. Competitive insights
    • 5.4.4.4. Mexico castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
• 5.5. Europe
  • 5.5.1. Europe castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5.2. UK
    • 5.5.2.1. Key country dynamics
    • 5.5.2.2. Regulatory framework
    • 5.5.2.3. Competitive insights
    • 5.5.2.4. UK castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5.3. Germany
    • 5.5.3.1. Key country dynamics
    • 5.5.3.2. Regulatory framework
    • 5.5.3.3. Competitive insights
    • 5.5.3.4. Germany castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5.4. France
    • 5.5.4.1. Key country dynamics
    • 5.5.4.2. Regulatory framework
    • 5.5.4.3. Competitive insights
    • 5.5.4.4. France castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5.5. Italy
    • 5.5.5.1. Key country dynamics
    • 5.5.5.2. Regulatory framework
    • 5.5.5.3. Competitive insights
    • 5.5.5.4. Italy castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5.6. Spain
    • 5.5.6.1. Key country dynamics
    • 5.5.6.2. Regulatory framework
    • 5.5.6.3. Competitive insights
    • 5.5.6.4. Spain castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5.7. Norway
    • 5.5.7.1. Key country dynamics
    • 5.5.7.2. Regulatory framework
    • 5.5.7.3. Competitive insights
    • 5.5.7.4. Norway castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5.8. Sweden
    • 5.5.8.1. Key country dynamics
    • 5.5.8.2. Regulatory framework
    • 5.5.8.3. Competitive insights
    • 5.5.8.4. Sweden castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5.9. Denmark
    • 5.5.9.1. Key country dynamics
    • 5.5.9.2. Regulatory framework
    • 5.5.9.3. Competitive insights
    • 5.5.9.4. Denmark castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
• 5.6. Asia Pacific
  • 5.6.1. Asia Pacific castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.6.2. Japan
    • 5.6.2.1. Key country dynamics
    • 5.6.2.2. Regulatory framework
    • 5.6.2.3. Competitive insights
    • 5.6.2.4. Japan castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.6.3. China
    • 5.6.3.1. Key country dynamics
    • 5.6.3.2. Regulatory framework
    • 5.6.3.3. Competitive insights
    • 5.6.3.4. China castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.6.4. India
    • 5.6.4.1. Key country dynamics
    • 5.6.4.2. Regulatory framework
    • 5.6.4.3. Competitive insights
    • 5.6.4.4. India castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.6.5. Thailand
    • 5.6.5.1. Key country dynamics
    • 5.6.5.2. Regulatory framework
    • 5.6.5.3. Competitive insights
    • 5.6.5.4. Thailand castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.6.6. South Korea
    • 5.6.6.1. Key country dynamics
    • 5.6.6.2. Regulatory framework
    • 5.6.6.3. Competitive insights
    • 5.6.6.4. South Korea castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.6.7. Australia
    • 5.6.7.1. Key country dynamics
    • 5.6.7.2. Regulatory framework
    • 5.6.7.3. Competitive insights
    • 5.6.7.4. Australia castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
• 5.7. Latin America
  • 5.7.1. Latin America castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.7.2. Brazil
    • 5.7.2.1. Key country dynamics
    • 5.7.2.2. Regulatory framework
    • 5.7.2.3. Competitive insights
    • 5.7.2.4. Brazil castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.7.3. Argentina
    • 5.7.3.1. Key country dynamics
    • 5.7.3.2. Regulatory framework
    • 5.7.3.3. Competitive insights
    • 5.7.3.4. Argentina castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
• 5.8. Middle East & Africa
  • 5.8.1. Middle East & Africa castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.8.2. South Africa
    • 5.8.2.1. Key country dynamics
    • 5.8.2.2. Regulatory framework
    • 5.8.2.3. Competitive insights
    • 5.8.2.4. South Africa castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.8.3. Saudi Arabia
    • 5.8.3.1. Key country dynamics
    • 5.8.3.2. Regulatory framework
    • 5.8.3.3. Competitive insights
    • 5.8.3.4. Saudi Arabia castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.8.4. UAE
    • 5.8.4.1. Key country dynamics
    • 5.8.4.2. Regulatory framework
    • 5.8.4.3. Competitive insights
    • 5.8.4.4. UAE castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.8.5. Kuwait
    • 5.8.5.1. Key country dynamics
    • 5.8.5.2. Regulatory framework
    • 5.8.5.3. Competitive insights
    • 5.8.5.4. Kuwait castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 6. Competitive Landscape

• 6.1. Participant Overview
• 6.2. Company Market Position Analysis
• 6.3. Company Categorization
• 6.4. Strategy Mapping
• 6.5. Company Profiles/Listing
  • 6.5.1. Sanofi
    • 6.5.1.1. Overview
    • 6.5.1.2. Financial performance
    • 6.5.1.3. Material benchmarking
    • 6.5.1.4. Strategic initiatives
  • 6.5.2. Johnson & Johnson Services, Inc.
    • 6.5.2.1. Overview
    • 6.5.2.2. Financial performance
    • 6.5.2.3. Material benchmarking
    • 6.5.2.4. Strategic initiatives
  • 6.5.3. Pfizer, Inc.
    • 6.5.3.1. Overview
    • 6.5.3.2. Financial performance
    • 6.5.3.3. Material benchmarking
    • 6.5.3.4. Strategic initiatives
  • 6.5.4. Astellas Pharma, Inc.
    • 6.5.4.1. Overview
    • 6.5.4.2. Financial performance
    • 6.5.4.3. Material benchmarking
    • 6.5.4.4. Strategic initiatives
  • 6.5.5. Bayer AG
    • 6.5.5.1. Overview
    • 6.5.5.2. Financial performance
    • 6.5.5.3. Material benchmarking
    • 6.5.5.4. Strategic initiatives

List of Tables

• Table 1. List of secondary sources
• Table 2. List of abbreviations
• Table 3. Castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
• Table 4. Castrate-resistant prostate cancer market, by region, 2018 - 2030 (USD Million)
• Table 5. North America castrate-resistant prostate cancer market, by country, 2018 - 2030 (USD Million)
• Table 6. North America castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
• Table 7. U.S. castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
• Table 8. Canada castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
• Table 9. Mexico castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
• Table 10. Europe castrate-resistant prostate cancer market, by country, 2018 - 2030 (USD Million)
• Table 11. Europe castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
• Table 12. UK castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
• Table 13. Germany castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
• Table 14. France castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
• Table 15. Italy castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
• Table 16. Spain castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
• Table 17. Norway castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
• Table 18. Sweden castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
• Table 19. Denmark castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
• Table 20. Asia Pacific castrate-resistant prostate cancer market, by country, 2018 - 2030 (USD Million)
• Table 21. Asia Pacific castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
• Table 22. China castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
• Table 23. Japan castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
• Table 24. India castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
• Table 25. Thailand castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
• Table 26. South Korea castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
• Table 27. Australia castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
• Table 28. Latin America castrate-resistant prostate cancer market, by country, 2018 - 2030 (USD Million)
• Table 29. Latin America crowns and bridges market, by therapy, 2018 - 2030 (USD Million)
• Table 30. Brazil castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
• Table 31. Agrnetina castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
• Table 32. Middle East & Africa castrate-resistant prostate cancer market, by country, 2018 - 2030 (USD Million)
• Table 33. Middle East & Africa crowns and bridges market, by therapy, 2018 - 2030 (USD Million)
• Table 34. South Africa castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
• Table 35. Saudi Arabia castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
• Table 36. UAE castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
• Table 37. Kuwait castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)

List of Figures